Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties

Pharmaceuticals

Volumn 3, Issue 11, 2010, Pages 3435-3460

  Seil, Michèle ^a   Nagant, Carole ^a   Dehaye, Jean Paul ^a   Vandenbranden, Michel ^a   Lensink, Marc Ferdinand ^b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIV LILLE   (France)

Author keywords

Antimicrobial peptides; Biofilm; Cathelicidin; Cell penetrating peptides; Formyl peptide receptors; LL 37

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CELL PENETRATING PEPTIDE; DEFENSIN; FORMYLPEPTIDE RECEPTOR LIKE 1; PURINERGIC P2X4 RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ALPHA HELIX; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ATOPIC DERMATITIS; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BIOFILM; CELLULAR IMMUNITY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CYTOTOXICITY; EUKARYOTIC CELL; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOMODULATION; INTERNALIZATION; LIPID BILAYER; LIPID COMPOSITION; NATURAL KILLER CELL; NONHUMAN; OLIGOMERIZATION; PHOSPHOLIPID BILAYER; PROKARYOTIC CELL; REVIEW; WOUND HEALING;

EID: 78650338718     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3113435     Document Type: Review

References (206)

1. Neuberger M.S. Novartis Medal Lecture. Antibodies: a paradigm for the evolution of molecular recognition. Biochem. Soc. Trans. 2002, 30, 341-350.
2. Hultmark, D.; Steiner, H.; Rasmuson, T.; Boman, H.G. Insect immunity. Purification and properties of three inducible bactericidal proteins from hemolymph of immunized pupae of Hyalophora cecropia. Eur. J. Biochem. 1980, 106, 7-16.
3. Wang, G.; Li, X.; Wang, Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic. Acids Res. 2009, 37, D933-D937.
4. Oppenheim, J.J.; Tewary, P.; de la Rosa, G.; Yang, D. Alarmins initiate host defense. Adv. Exp. Med. Biol. 2007, 601, 185-194.
5. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 2003, 3, 710-720.
6. Bals, R.; Wilson, J.M. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci. 2003, 60, 711-720.
7. Kavanagh, K.; Dowd, S. Histatins: antimicrobial peptides with therapeutic potential. J. Pharm. Pharmacol. 2004, 56, 285-289.
8. Brogden, K.A.; Guthmiller, J.M.; Salzet, M.; Zasloff, M. The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 2005, 6, 558-564.
9. Gifford, J.L.; Hunter, H.N.; Vogel, H.J. Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci. 2005, 62, 2588-2598.
10. Baechle, D.; Flad, T.; Cansier, A.; Steffen, H.; Schittek, B.; Tolson, J.; Herrmann, T.; Dihazi, H.; Beck, A.; Mueller, G.A.; Mueller, M.; Stevanovic, S.; Garbe, C.; Mueller, C.A.; Kalbacher, H. Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L. J. Biol. Chem. 2006, 281, 5406-5415.
11. Soscia, S.J.; Kirby, J.E.; Washicosky, K.J.; Tucker, S.M.; Ingelsson, M.; Hyman, B.; Burton, M.A.; Goldstein, L.E.; Duong, S.; Tanzi, R.E.; Moir, R.D. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010, 5, e9505.
12. Goumon, Y.; Lugardon, K.; Kieffer, B.; Lefèvre, J.F.; Van Dorsselaer, A.; Aunis, D.; MetzBoutigue, M.H. Characterization of antibacterial COOH-terminal proenkephalin-A-derived peptides (PEAP) in infectious fluids. Importance of enkelytin, the antibacterial PEAP209-237 secreted by stimulated chromaffin cells. J. Biol. Chem. 1998, 273, 29847-29856.
13. Dobson, C.B.; Sales, S.D.; Hoggard, P.; Wozniak, M.A.; Crutcher, K.A. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J. Infect. Dis. 2006, 193, 442-450.
14. Kelly, B.A.; Harrison, I.; McKnight, A.; Dobson, C.B. Anti-infective activity of apolipoprotein domain derived peptides in vitro: identification of novel antimicrobial peptides related to apolipoprotein B with anti-HIV activity. BMC Immunol. 2010, 11, 13.
15. Srinivas, R.V.; Venkatachalapathi, Y.V.; Rui, Z.; Owens, R.J.; Gupta, K.B.; Srinivas, S.K.; Anantharamaiah, G.M.; Segrest, J.P.; Compans, R.W. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J. Cell. Biochem. 1991, 45, 224-237.
16. Malmsten, M.; Davoudi, M.; Schmidtchen, A. Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. Matrix Biol. 2006, 25, 294-300.
17. a, from invertebrates to humans. J. Biol. Chem. 2007, 282, 2520-2528.
18. Nguyen, T.X.; Cole, A.M.; Lehrer, R.I. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003, 24, 1647-1654.
19. Maemoto, A.; Qu, X.; Rosengren, K.J.; Tanabe, H.; Henschen-Edman, A.; Craik, D.J.; Ouellette, A.J. Functional analysis of the alpha-defensin disulfide array in mouse cryptdin-4. J. Biol. Chem. 2004, 279, 44188-44196.
20. Rajabi, M.; de Leeuw, E.; Pazgier, M.; Li, J.; Lubkowski, J.; Lu, W. The conserved salt bridge in human alpha-defensin 5 is required for its precursor processing and proteolytic stability. J. Biol. Chem. 2008, 283, 21509-21518.
21. Ganz, T.; Lehrer, R.I. Defensins. Curr. Opin. Immunol. 1994, 4, 584-589.
22. Jia, H.P.; Schutte, B.C.; Schudy, A.; Linzmeier, R.; Guthmiller, J.M.; Johnson, G.K.; Tack, B.F.; Mitros, J.P.; Rosenthal, A.; Ganz, T.; McCray, P.B., Jr. Discovery of new human beta-defensins using a genomics-based approach. Gene 2001, 263, 211-218.
23. Yang, D.; Chertov, O.; Bykovskaia, S.N.; Chen, Q.; Buffo, M.J.; Shogan, J.; Anderson, M.; Schröder, J.M.; Wang, J.M.; Howard, O.M.; Oppenheim, J.J. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286, 525-528.
24. Michaelson, D.; Rayner, J.; Couto, M.; Ganz, T. Cationic defensins arise from charge neutralized propeptides: a mechanism for avoiding leukocyte autocytotoxicity? J. Leukoc. Biol. 1992, 51, 634-639.
25. Ghosh, D.; Porter, E.; Shen, B.; Lee, S.K.; Wilk, D.; Drazba, J.; Yadav, S.P.; Crabb, J.W.; Ganz, T.; Bevins, C.L. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat. Immunol. 2002, 3, 583-590.
26. Shaw, J.L.; Petraki, C.; Watson, C.; Bocking, A.; Diamandis, E.P. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. Biol. Chem. 2008, 389, 1513-1522.
27. Wilson, C.L.; Schmidt, A.P.; Pirilä, E.; Valore, E.V.; Ferri, N.; Sorsa, T.; Ganz, T.; Parks, W.C. Differential processing of α - and β-defensin precursors by matrix metalloproteinase- 7 (MMP-7). J. Biol. Chem. 2009, 284, 8301-8311.
28. Bevins, C.L. Paneth cell defensins: key effector molecules of innate immunity. Biochem. Soc. Trans. 2006, 34, 263-266.
29. Yamaguchi, Y.; Nagase, T.; Tomita, T.; Nakamura, K.; Fukuhara, S.; Amano, T.; Yamamoto, H.; Ide, Y.; Suzuki, M.; Teramoto, S.; Asano, T.; Kangawa, K.; Nakagata, N.; Ouchi, Y.; Kurihara, H. Beta-defensin overexpression induces progressive muscle degeneration in mice. Am. J. Physiol. Cell. Physiol. 2007, 292, C2141-C2149.
30. Huang, L.; Ching, C.B.; Jiang, R.; Leong, S.S. Production of bioactive human beta-defensin 5 and 6 in Escherichia coli by soluble fusion expression. Protein Expr. Purif. 2008, 61, 168-174.
31. Yenugu, S.; Hamil, K.G.; French, F.S.; Hall, S.H. Antimicrobial actions of the human epididymis 2 (HE2) protein isoforms, HE2alpha, HE2beta1 and HE2beta2. Reprod. Biol. Endocrinol. 2004, 2, 61.
32. Yount, N.Y.; Yeaman, M.R. Multidimensional signatures in antimicrobial peptides. Proc. Natl Acad. Sci. USA 2004, 101, 7363-7368.
33. Agerberth, B.; Lee, J.Y.; Bergman, T.; Carlquist, M.; Boman, H.G.; Mutt, V.; Jörnvall, H. Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of prolinearginine- rich antibacterial peptides. Eur. J. Biochem. 1991, 202, 849-854.
34. Zanetti, M.; Gennaro, R.; Romeo, D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995, 374, 1-5.
35. Sørensen, O.; Arnljots, K.; Cowland, J.B.; Bainton, D.F.; Borregaard, N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997, 90, 2796-2803.
36. Malm, J.; Sørensen, O.; Persson, T.; Frohm-Nilsson, M.; Johansson, B.; Bjartell, A.; Lilja, H.; Ståhle-Bäckdahl, M.; Borregaard, N.; Egesten, A. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect. Immun. 2000, 68, 4297-4302.
37. Bals, R.; Wang, X.; Zasloff, M.; Wilson, J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA 1998, 95, 9541-9546.
38. Agerberth, B.; Grunewald, J.; Castaños-Velez, E.; Olsson, B.; Jörnvall, H.; Wigzell, H.; Eklund, A.; Gudmundsson, G.H. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am. J. Respir. Crit. Care Med. 1999, 160, 283-290.
39. Lee, D.Y.; Yamasaki, K.; Rudsil, J.; Zouboulis, C.C.; Park, G.T.; Yang, J.M.; Gallo, R.L. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J. Invest. Dermatol. 2008, 128, 1863-1866.
40. Braff, M.H.; Zaiou, M.; Fierer, J.; Nizet, V.; Gallo, R.L. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. Infect. Immun. 2005, 73, 6771-6781.
41. Di Nardo, A.; Braff, M.H.; Taylor, K.R.; Na, C.; Granstein, R.D.; McInturff, J.E.; Krutzik, S.; Modlin, R.L.; Gallo, R.L. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 2007, 178, 1829-1834.
42. Sørensen, O.; Bratt, T.; Johnsen, A.H.; Madsen M.T.; Borregaard, N. The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma. J. Biol. Chem. 1999, 274, 22445-22451.
43. Zaiou, M.; Nizet, V.; Gallo, R.L. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 2003, 120, 810-816.
44. Agerberth, B.; Gunne, H.; Odeberg, J.; Kogner, P.; Boman, H.G.; Gudmundsson, G.H. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci. USA 1995, 92, 195-199.
45. Larrick, J.W.; Lee, J.; Ma, S.; Li, X.; Francke, U.; Wright, S.C.; Balint, R.F. Structural, functional analysis and localization of the human CAP18 gene. FEBS Lett. 1996, 398, 74-80.
46. Yustein, A.S.; Harper, J.C.; Petroni, G.R.; Cummings, O.W.; Moskaluk, C.A.; Powell, S.M. Allelotype of gastric adenocarcinoma. Cancer Res. 1999, 59, 1437-1441.
47. Hase, K.; Murakami, M.; Iimura, M; Cole, S.P.; Horibe, Y.; Ohtake, T.; Obonyo, M.; Gallo, R.L.; Eckmann, L.; Kagnoff, M.F. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 2003, 125, 1613-1625.
48. Wu, W.K.; Sung, J.J.; To, K.F.; Yu, L.; Li, H.T.; Li, Z.J.; Chu, K.M.; Yu, J.; Cho, C.H. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J. Cell. Physiol. 2010, 223, 178-186.
49. Gudmundsson, G.H.; Agerberth, B.; Odeberg, J.; Bergman, T.; Olsson, B.; Salcedo, R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 1996, 238, 325-332.
50. Larrick, J.W.; Hirata, M.; Balint, R.F.; Lee, J.; Zhong, J.; Wright, S.C. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 1995, 63, 1291-1297.
51. Sørensen, O.E.; Follin, P.; Johnsen, A.H.; Calafat, J.; Tjabringa, G.S.; Hiemstra, P.S.; Borregaard, N. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97, 3951-3959.
52. Sørensen, O.; Gram, L.; Johnsen, A.H.; Andersson, E.; Bangsbøll, S.; Tjabringa, G.S.; Hiemstra, P.S.; Malm, J.; Egesten, A.; Borregaard, N.E. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem. 2003, 278, 28540-28546.
53. Murakami, M.; Lopez-Garcia, B.; Braff, M.; Dorschner, R.A.; Gallo, R.L. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. 2004, 172, 3070-3077.
54. Yamasaki, K.; Schauber, J.; Coda, A.; Lin, H.; Dorschner, R.A.; Schechter, N.M.; Bonnart, C.; Descargues, P.; Hovnanian, A.; Gallo, R.L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006, 20, 2068-2080.
55. Turner, J.; Cho, Y.; Dihn, N.-N.; Waring, A.J.; Lehrer, R.I. Activities of LL-37, a cathelinassociated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 1998, 42, 2206-2214.
56. Nagaoka, I.; Hirota, S.; Yomogida, S.; Ohwada, A.; Hirata, M. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm. Res. 2000, 49, 73-79.
57. Yang, D.; Chen, Q.; Schmidt, A.P.; Anderson, G.M.; Wang, J.M.; Wooters, J.; Oppenheim, J.J.; Chertov, O. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000, 192, 1069-1074.
58. Johansson, J.; Gudmundsson, G.H.; Rottenberg, M.E.; Berndt, K.D.; Agerberth, B. Conformationdependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 1998, 273, 3718-3724.
59. Leung, D.Y.; Boguniewicz, M.; Howell, M.D.; Nomura, I.; Hamid, Q.A. New insights into atopic dermatitis. J. Clin. Invest. 2004, 113, 651-657.
60. Ong, P.Y.; Ohtake, T.; Brandt, C.; Strickland, I.; Boguniewicz, M.; Ganz, T.; Gallo, R.L.; Leung, D.Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. New Engl. J. Med. 2002, 347, 1151-1160.
61. Büchau, A.S.; Schauber, J.; Hultsch, T.; Stuetz, A.; Gallo, R.L. Pimecrolimus enhances TLR2/6- induced expression of antimicrobial peptides in keratinocytes. J. Invest. Dermatol. 2008, 128, 2646-2654.
62. Rosenberger, C.M.; Gallo, R.L.; Finlay, B.B. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl. Acad. Sci. USA 2004, 101, 2422-2427.
63. Bergman, P.; Johansson, L.; Wan, H.; Jones, A.; Gallo, R.L.; Gudmundsson, G.H.; Hökfelt, T.; Jonsson, A.B.; Agerberth, B. Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect. Immun. 2006, 74, 6982-6991.
64. Chromek, M.; Slamová, Z.; Bergman, P.; Kovács, L.; Podracká, L.; Ehrén, I.; Hökfelt, T.; Gudmundsson, G.H.; Gallo, R.L.; Agerberth, B.; Brauner, A. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 2006, 12, 636-641.
65. Bals, R.; Weiner, D.J.; Moscioni, A.D.; Meegalla, R.L.; Wilson, J.M. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 1999, 67, 6084-6089.
66. Bals, R.; Weiner, D.J.; Meegalla, R.L.; Wilson, J.M. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Invest. 1999, 103, 1113-1117.
67. Zanetti, M. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 2005, 7, 179-196.
68. Gutsmann, T.; Larrick, J.W.; Seydel, U.; Wiese, A. Molecular mechanisms of interaction of rabbit CAP18 with outer membranes of gram-negative bacteria. Biochemistry. 1999, 38, 13643-13653.
69. Oren, Z.; Lerman, J.C.; Gudmundsson, G.H.; Agerberth, B.; Shai, Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 1999, 341, 501-513.
70. Morgera, F.; Vaccari, L.; Antcheva, N.; Scaini, D.; Pacor, S.; Tossi, A. Primate cathelicidin orthologues display different structures and membrane interactions. Biochem. J. 2009, 417, 727-735.
71. Zhang, X.; Oglecka, K.,; Sandgren, S.; Belting, M.; Esbjörner, E.K.; Nordén, B.; Gräslund, A. Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochim. Biophys. Acta 2010, doi://dx.doi.org/10.1016/j.bbamem.2009.12.011.
72. Tomasinsig, L.; Morgera, F.; Antcheva, N.; Pacor, S.; Skerlavaj, B.; Zanetti, M.; Tossi, A. Structure dependence of biological activities for primate cathelicidins. J. Pept. Sci. 2009, 15, 576-582.
73. Henzler Wildman, K.A.; Lee, D.K.; Ramamoorthy, A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003, 42, 6545-6558.
74. Porcelli, F.; Verardi, R.; Shi, L.; Henzler Wildman, K.A.; Ramamoorthy, A.; Veglia, G. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. Biochemistry 2008, 47, 5565-5572.
75. Porcelli, F.; Buck, B.; Lee, D.K.; Hallock, K.J.; Ramamoorthy, A.; Veglia, G. Structure and orientation of pardaxin determined by NMR experiments in model membranes. J. Biol. Chem. 2004, 279, 45815-45823.
76. Wang, G. Structure, dynamics and mapping of membrane-binding residues of micelle-bound antimicrobial peptides by natural abundance 13C NMR spectroscopy. Biochim. Biophys. Acta 2010, 1798, 114-121.
77. Neville, F.; Cahuzac, M.; Konovalov, O.; Ishitsuka, Y.; Lee, K.Y.; Kuzmenko, I.; Kale, G.M.; Gidalevitz, D. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys. J. 2006, 90, 1275-1287.
78. Wu, M.; Maier, E.; Benz, R.; Hancock, R.E. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 1999, 38, 7235-7242.
79. Epand, R.M.; Epand, R.F.; Arnusch, C.J.; Papahadjopoulos-Sternberg, B.; Wang, G.; Shai, Y. Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim. Biophys. Acta 2010, 1798, 1272-1280.
80. Pabst, G.; Grage, S.L.; Danner-Pongratz, S.; Jing, W.; Ulrich, A.S.; Watts, A.; Lohner, K.: Hickel, A. Membrane thickening by the antimicrobial peptide PGLa. Biophys. J. 2008, 95, 5779-5788.
81. Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta 2009, 1788, 1687-1692.
82. Gennaro, R.; Zanetti, M. Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000, 55, 31-49.
83. Hancock, R.E.; Diamond, G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 2000, 8, 402-410.
84. Lehrer, R.I.; Lichtenstein, A.K.; Ganz, T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu. Rev. Immunol. 1993, 11, 105-128.
85. Risso, A. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J. Leukoc. Biol. 2000, 68, 785-792.
86. Boheim, G.; Hanke, W.; Eibl, H. Lipid phase transition in planar bilayer membrane and its effect on carrier- and pore-mediated ion transport. Proc. Natl. Acad. Sci. USA 1980, 77, 3403-3407.
87. Heller, W.T.; Waring, A.J.; Lehrer, R.I.; Harroun, T.A.; Weiss, T.M.; Yang, L.; Huang, H.W. Membrane thinning effect of the beta-sheet antimicrobial protegrin. Biochemistry 2000, 39, 139-145.
88. Henzler Wildman, K.A.; Martinez, G.V.; Brown, M.F.; Ramamoorthy, A. Perturbation of the hydrophobic core of lipid bilayers by the human antimicrobial peptide LL-37. Biochemistry 2004, 43, 8459-8469.
89. Turner, J.; Cho, Y.; Dihn, N.-N.; Waring, A.J.; Lehrer, R.I. Activities of LL-37, a cathelinassociated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 1998, 42, 2206-2214.
90. Wang, G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem. 2008, 283, 32637-32643.
91. Li, X.; Li, Y.; Han, H.; Miller, D.W.; Wang, G. Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J. Am. Chem. Soc. 2006, 128, 5776-5785.
92. Li, Y.; Li, X.; Li, H.; Lockridge, O.; Wang, G. A novel method for purifying recombinant human host defense cathelicidin LL-37 by utilizing its inherent property of aggregation. Protein Expr. Purif. 2007, 54, 157-165.
93. Kirikae, T.; Hirata, M.; Yamasu, H.; Kirikae, F.; Tamura, H.; Kayama, F.; Nakatsuka, K.; Yokochi, T.; Nakano, M. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect. Immun. 1998, 66, 1861-1868.
94. Nagaoka, I.; Hirota, S.; Niyonsaba, F.; Hirata, M.; Adachi, Y.; Tamura, H.; Tanaka, S.; Heumann, D. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin. Diagn. Lab. Immunol. 2002, 9, 972-982.
95. Epand, R.F.; Wang, G.; Berno, B.; Epand, R.M. Lipid segregation explains selective toxicity of a series of fragments derived from the human cathelicidin LL-37. Antimicrob. Agents Chemother. 2009, 53, 3705-3714.
96. Howl, J.; Nicholl, I.D.; Jones, S. The many futures for cell-penetrating peptides: how soon is now? Biochem. Soc. Trans. 2007, 35, 767-769.
97. Shaw, J.E.; Epand, R.F.; Hsu, J.C.; Mo, G.C.; Epand, R.M.; Yip, C.M. Cationic peptide-induced remodelling of model membranes: direct visualization by in situ atomic force microscopy. J. Struct. Biol. 2008, 162, 121-138.
98. Lamazière, A.; Maniti, O.; Wolf, C.; Lambert, O.; Chassaing, G.; Trugnan, G.; Ayala-Sanmartin, J. Lipid domain separation, bilayer thickening and pearling induced by the cell penetrating peptide penetratin. Biochim Biophys Acta 2010, 1798, 2223-2230.
99. Henriques, S.T.; Quintas, A.; Bagatolli, L.A.; Homblé, F.; Castanho, M.A. Energy-independent translocation of cell-penetrating peptides occurs without formation of pores. A biophysical study with pep-1. Mol. Membr. Biol. 2007, 24, 282-293.
100. Henriques, S.T.; Castanho, M.A.; Pattenden, L.K.; Aguilar, M.I. Fast membrane association is a crucial factor in the peptide pep-1 translocation mechanism: a kinetic study followed by surface plasmon resonance. Biopolymers 2010, 94, 314-322.
101. Lensink, M.F.; Christiaens, B.; Vandekerckhove, J.; Prochiantz, A.; Rosseneu, M. title type=contributor>Penetratinmembrane association: W48/R52/W56 shield the peptide from the aqueous phase. Biophys. J. 2005, 88, 939-952.
102. Konate, K.; Crombez, L.; Deshayes, S.; Decaffmeyer, M.; Thomas, A.; Brasseur, R.; Aldrian, G.; Heitz, F.; Divita, G. Insight into the cellular uptake mechanism of a secondary amphipathic cellpenetrating peptide for siRNA delivery. Biochemistry 2010, 49, 3393-3402.
103. Crombez, L.; Aldrian-Herrada, G.; Konate, K.; Nguyen, Q.N.; McMaster, G.K.; Brasseur, R.; Heitz, F.; Divita, G. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther. 2009, 17, 95-103.
104. Balayssac, S.; Burlina, F.; Convert, O.; Bolbach, G.; Chassaing, G.; Lequin, O. Comparison of penetratin and other homeodomain-derived cell-penetrating peptides: interaction in a membranemimicking environment and cellular uptake efficiency. Biochemistry 2006, 45, 1408-1420.
105. Herce, H.D.; Garcia, A.E. Cell penetrating peptides: how do they do it? J. Biol. Phys. 2007, 33, 345-356.
106. Yesylevskyy, S.; Marrink, S.J.; Mark, A.E. Alternative mechanisms for the interaction of the cellpenetrating peptides penetratin and the TAT peptide with lipid bilayers. Biophys. J. 2009, 97, 40-49.
107. Afonin, S.; Frey, A.; Bayerl, S.; Fischer, D.; Wadhwani, P.; Weinkauf, S.; Ulrich, A.S. The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes. Chemphyschem 2006, 7, 2134-2142.
108. Tang, M.; Waring, A.J.; Hong, M. Phosphate-mediated arginine insertion into lipid membranes and pore formation by a cationic membrane peptide from solid-state NMR. J. Am. Chem. Soc. 2007, 129, 11438-11446.
109. Su, Y.; Doherty, T.; Waring, A.J.; Ruchala, P.; Hong, M. Roles of arginine and lysine residues in the translocation of a cell-penetrating peptide from (13)C, (31)P, and (19)F solid-state NMR. Biochemistry 2009, 48, 4587-4595.
110. Gonçalves, E.; Kitas, E.; Seelig, J. Binding of oligoarginine to membrane lipids and heparin sulfate: structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry 2005, 44, 2692-2702.
111. Esbjörner, E.K.; Lincoln, P.; Nordén, B. Counterion-mediated membrane penetration: cationic cell-penetrating peptides overcome Born energy barrier by ion-pairing with phospholipids. Biochim. Biophys. Acta. 2007, 1768, 1550-1558.
112. Amand, H.L.; Fant, K.; Nordén, B.; Esbjörner, E.K. Stimulated endocytosis in penetratin uptake: effect of arginine and lysine. Biochem. Biophys. Res. Commun. 2008, 371, 621-625.
113. Pantos, A.; Tsogas, I.; Paleos, C.M. Guanidinium group: a versatile moiety inducing transport and multicompartmentalization in complementary membranes. Biochim. Biophys. Acta. 2008, 1778, 811-823.
114. Schmidt, N.; Mishra, A.; Lai, G.H.; Wong, G.C. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010, 584, 1806-1813.
115. Herce, H.D.; Garcia, A.E.; Litt, J.; Kane, R.S.; Martin, P.; Enrique N.; Rebolledo, A.; Milesi, V. Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell penetrating peptides. Biophys. J. 2009, 97, 1917-1925.
116. Gunn, J.S.; Lim, K.B.; Krueger, J.; Kim, K.; Guo, L.; Hackett, M.; Miller, S.I. PmrA-PmrBregulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol. Microbiol. 1998, 27, 1171-1182.
117. Guo, L.; Lim, K.B.; Poduje, C.M.; Daniel, M.; Gunn, J.S.; Hackett, M.; Miller, S.I. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998, 95, 189-198.
118. Peschel, A.; Otto, M.; Jack, R.W.; Kalbacher, H.; Jung, G.; Götz, F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 1999, 274, 8405-8410.
119. Peschel, A.; Jack, R.W.; Otto, M.; Collins, L.V.; Staubitz, P.; Nicholson, G.; Kalbacher, H.; Nieuwenhuizen, W.F.; Jung, G.; Tarkowski, A.; van Kessel, K.P.; van Strijp, J.A. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 2001, 193, 1067-1076.
120. Guina, T.; Yi, E.C.; Wang, H.; Hackett, M.; Miller, S.I. A PhoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J. Bacteriol. 2000, 182, 4077-4086.
121. Shafer, W.M.; Qu, X.; Waring, A.J.; Lehrer, R.I. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/ nodulation/division efflux pump family. Proc. Natl. Acad. Sci. USA 1998, 95, 1829-1833.
122. Frick, I.M.; Akesson, P.; Rasmussen, M.; Schmidtchen, A.; Björck, L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J. Biol. Chem. 2003, 278, 16561-16566.
123. Islam, D.; Bandholtz, L.; Nilsson, J.; Wigzell, H.; Christensson, B.; Agerberth, B.; Gudmundsson, G. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat. Med. 2001, 7, 180-185.
124. Waite, R.D.; Paccanaro, A.; Papakonstantinopoulou, A.; Hurst, J.M.; Saqi, M.; Littler, E.; Curtis, M.A. Clustering of Pseudomonas aeruginosa transcriptomes from planktonic cultures, developing and mature biofilms reveals distinct expression profiles. BMC Genom. 2006, 7, 162.
125. Hall-Stoodley, L.; Stoodley, P. Developmental regulation of microbial biofilms. Curr. Opin. Biotechnol. 2002, 13, 228-233.
126. Monds, R.D.; O'Toole, G.A. The developmental model of microbial biofilms: ten years of a paradigm up for review. Trends Microbiol. 2009, 17, 73-87.
127. Tré-Hardy, M.; Vanderbist, F.; Traore, H.; Devleeschouwer, M.J. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int. J. Antimicrob. Agents 2008, 31, 329-336.
128. Nickel, J.C.; Ruseska, I.; Wright, J.B.; Costerton, J.W. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob. Agents Chemother. 1985, 27, 619-624.
129. Mah, T.F.; Pitts, B.; Pellock, B.; Walker, G.C.; Stewart, P.S.; O'Toole, G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003, 426, 306-310.
130. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 2010, 35, 322-332.
131. Vuong, C.; Voyich, J.M.; Fischer, E.R.; Braughton, K.R.; Whitney, A.R.; DeLeo, F.R.; Otto, M. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell. Microbiol. 2004, 6, 269-275.
132. Vuong, C.; Kocianova, S.; Voyich, J.M.; Yao, Y.; Fischer, E.R.; DeLeo, F.R.; Otto, M. A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. J. Biol. Chem. 2004, 279, 54881-54886.
133. Cirioni, O.; Giacometti, A.; Ghiselli, R.; Bergnach, C.; Orlando, F.; Mocchegiani, F.; Silvestri, C.; Licci, A.; Skerlavaj, B.; Zanetti, M.; Saba, V.; Scalise, G. Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 2006, 27, 2104-2110.
134. Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.; Rehm, B.H.; Hancock, R. E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176-4182.
135. Chennupati, S.K.; Chiu, A.G.; Tamashiro, E.; Banks, C.A.; Cohen, M.B.; Bleier, B.S.; Kofonow, J.M.; Tam, E.; Cohen, N.A. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am. J. Rhinol. Allergy 2009, 23, 46-51.
136. Hell, E.; Giske, C.G.; Nelson, A.; Römling, U.; Marchini, G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett. Appl. Microbiol. 2010, 50, 211-215.
137. Amer, L.S.; Bishop, B. M.; van Hoek, M.L. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem. Biophys. Res. Comm. 2010, 396, 246-251.
138. McPhee, J.B.; Hancock, R.E. Function and therapeutic potential of host defence peptides. J. Pept. Sci. 2005, 11, 677-687.
139. Sood, R.; Kinnunen, P.K. Cholesterol, lanosterol, and ergosterol attenuate the membrane association of LL-37(W27F) and temporin L. Biochim. Biophys. Acta 2008, 1778, 1460-1466.
140. Ciornei, C.D.; Sigurdardóttir, T.; Schmidtchen, A.; Bodelsson, M. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob. Agents Chemother. 2005, 49, 2845-2850.
141. Nagaoka, I.; Tamura, H.; Hirata, M. An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J. Immunol. 2006, 176, 3044-3052.
142. Koczulla, R.; von Degenfeld, G.; Kupatt, C.; Krötz, F.; Zahler, S.; Gloe, T.; Issbrücker, K.; Unterberger, P.; Zaiou, M.; Lebherz, C.; Karl, A.; Raake, P.; Pfosser, A.; Boekstegers, P.; Welsch, U.; Hiemstra, P.S.; Vogelmeier, C.; Gallo, R.L.; Clauss, M.; Bals, R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 2003, 111, 1665-1672.
143. Zhang, Z.; Cherryholmes, G.; Chang, F.; Rose, D.M.; Schraufstatter, I.; Shively, J.E. Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur. J. Immunol. 2009, 39, 3181-3194.
144. Brandenburg, L.O.; Jansen, S.; Wruck, C.J.; Lucius, R.; Pufe, T. Antimicrobial peptide rCRAMP induced glial cell activation through P2Y receptor signalling pathways. Mol. Immunol. 2010, 47, 1905-1913.
145. Yoshioka, M.; Fukuishi, N.; Kubo, Y.; Yamanobe, H.; Ohsaki, K.; Kawasoe, Y.; Murata, M.; Ishizumi, A.; Nishii, Y.; Matsui, N.; Akagi, M.Human cathelicidin CAP18/LL-37 changes mast cell function toward innate immunity. Biol. Pharm. Bull. 2008, 31, 212-216.
146. Niyonsaba, F.; Someya, A.; Hirata, M.; Ogawa, H.; Nagaoka, I. Evaluation of the effects of peptide antibiotics human β-defensins-1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur. J. Immunol. 2001, 31, 1066-1075.
147. Chen, X.; Niyonsaba, F.; Ushio, H.; Nagaoka, I.; Ikeda, S.; Okumura, K.; Ogawa, H. title type=contributor>Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J. Dermatol. Sci. 2006, 43, 63-66.
148. Elssner, A.; Duncan, M.; Gavrilin, M.; Wewers, M.D. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 2004, 172, 4987-4994.
149. Skaper, S.D.; Debetto, P.; Giusti, P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2010, 24, 337-345.
150. Weinhold, K.; Krause-Buchholz, U.; Rödel, G.; Kasper, M.; Barth, K. Interaction and interrelation of P2X7 and P2X4 receptor complexes in mouse lung epithelial cells. Cell. Mol. Life Sci. 2010, 67, 2631-2642.
151. Tomasinsig, L.; Pizzirani, C.; Skerlavaj, B.; Pellegatti, P.; Gulinelli, S.; Tossi, A.; Di Virgilio, F.; Zanetti, M. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J. Biol. Chem. 2008, 283, 30471-30481.
152. Shaykhiev, R.; Beisswenger, C.; Kändler, K.; Senske, J.; Püchner, A.; Damm, T.; Behr, J.; Bals, R. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 289, L842-L848.
153. Coffelt, S.B.; Tomchuck, S.L.; Zwezdaryk, K.J.; Danka, E.S.; Scandurro, A.B. Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol. Cancer Res. 2009, 7, 907-915.
154. Coffelt, S.B.; Waterman, R.S.; Florez, L.; Höner zu Bentrup, K.; Zwezdaryk, K.J.; Tomchuck, S.L.; LaMarca, H.L.; Danka, E.S.; Morris, C.A.; Scandurro, A.B. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer. 2008, 122, 1030-1039.
155. von Haussen, J.; Koczulla, R.; Shaykhiev, R.; Herr, C.; Pinkenburg, O.; Reimer, D.; Wiewrodt, R.; Biesterfeld, S.; Aigner, A.; Czubayko, F.; Bals, R. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 2008, 59, 12-23.
156. Weber, G.; Chamorro, C.I.; Granath, F.; Liljegren, A.; Zreika, S.; Saidak, Z.; Sandstedt, B.; Rotstein, S.; Mentaverri, R.; Sánchez, F.; Pivarcsi, A.; Ståhle, M. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res. 2009, 11, R6.
157. Ohtsu, H.; Dempsey, P.J.; Eguchi, S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell. Physiol. 2006, 291, C1-C10.
158. Seil, M.; Kabré, E.; Nagant, C.; Vandenbranden, M.; Fontanils, U.; Marino, A.; Pochet, S.; Dehaye, J.P. Regulation by CRAMP of the responses of murine peritoneal macrophages to extracellular ATP. Biochim. Biophys. Acta. 2010, 1798, 569-578.
159. Zughaier, S.M.; Shafer, W.M.; Stephens, D.S. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell. Microbiol. 2005, 7, 1251-1262.
160. Di Nardo, A.; Braff, M.H.; Taylor, K.R.; Na, C.; Granstein, R.D.; McInturff, J.E.; Krutzik, S.; Modlin, R.L.; Gallo, R.L. Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. 2007, 178, 1829-1834.
161. Pochet, S.; Tandel, S.; Querriére, S.; Tré-Hardy, M.; Garcia-Marcos, M.; De Lorenzi, M.; Vandenbranden, M.; Marino, A.; Devleeschouwer, M.; Dehaye, J.P. Modulation by LL-37 of the responses of salivary glands to purinergic agonists. Mol. Pharmacol. 2006, 69, 2037-2046.
162. Rao; N.M. Differential susceptibility of phosphatidylcholine small unilamellar vesicles to phospholipases A2, C and D in the presence of membrane active peptides. Biochem. Biophys. Res. Commun. 1992, 182, 682-688.
163. Perregaux, D.G.; Bhavsar, K.; Contillo, L.; Shi, J.; Gabel, C.A. Antimicrobial peptides initiate IL-1β posttranslational processing: a novel role beyond innate immunity. J. Immunol. 2002, 168, 3024-3032.
164. Wewers, M.D.; Sarkar, A. P2X7 receptor and macrophage function. Purinergic Signal. 2009, 5, 189-195.
165. Denlinger, L.C.; Fisette, P.L.; Sommer, J.A.; Watters, J.J.; Prabhu, U.; Dubyak, G.R.; Proctor, R.A.; Bertics, P.J. Cutting edge: the nucleotide receptor P2X7 contains multiple protein- and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J. Immunol. 2001, 167, 1871-1876.
166. Sandgren, S.; Wittrup, A.; Cheng, F.; Jönsson, M.; Eklund, E.; Busch, S.; Belting, M. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis. J. Biol. Chem. 2004, 279, 17951-17956.
167. Garcia-Marcos, M.; Dehaye, J.P.; Marino, A. Membrane compartments and purinergic signalling: the role of plasma membrane microdomains in the modulation of P2XR-mediated signalling. FEBS J. 2009, 276, 330-340.
168. Mookherjee, N.; Lippert, D.N.; Hamill, P.; Falsafi, R.; Nijnik, A.; Kindrachuk, J.; Pistolic, J.; Gardy, J.; Miri, P.; Naseer, M.; Foster, L.J.; Hancock, R.E. Intracellular receptor for human host defense peptide LL-37 in monocytes. J. Immunol. 2009, 183, 2688-2696.
169. Sebbage, V. Cell-penetrating peptides and their therapeutic applications. Bioscience Horizons 2009, 2, 64-72.
170. Hällbrink, M.; Kilk, K.; Elmquist, A.; Lundberg, P.; Lindgren, M.; Jiang, Y.; Pooga, M.; Soomets, U.; Langel, U. Prediction of cell-penetrating peptides. Int. J. Pep. Res. Ther. 2005, 11, 249-259.
171. Derossi, D.; Joliot, A.H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994, 1269, 10444-10450.
172. Vivès, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010-16017.
173. Fischer, R.; Köhler, K.; Fotin-Mleczek, M.; Brock, R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 2004, 279, 12625-12635.
174. Chaloin, L.; Vidal, P.; Heitz, A.; Van Mau, N.; Mery, J.; Divita, G.; Heitz, F. Conformations of primary amphipathic carrier peptides in membrane mimicking environments. Biochemistry 1997, 36, 11179-11187.
175. Vidal, P.; Chaloin, L.; Heitz, A.; Van Mau, N.; Mery, J.; Divita, G.; Heitz, F. Interactions of primary amphipathic vector peptides with membranes. Conformational consequences and influence on cellular localization. J. Membr. Biol. 1998, 162, 259-264.
176. Magzoub, M.; Eriksson, L.E.; Gräslund, A. Comparison of the interaction, positioning, structure induction and membrane perturbation of cell-penetrating peptides and non-translocating variants with phospholipid vesicles. Biophys. Chem. 2003, 103, 271-288.
177. Barany-Wallje, E.; Andersson, A.; Gräslund, A.; Maler, L. NMR solution structure and position of transportan in neutral phospholipid bicelles. FEBS Lett. 2004, 567, 265-269.
178. Deshayes, S.; Plenat, T.; Aldrian-Herrada, G.; Divita, G.; Le Grimellec, C.; Heitz, F. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 2004, 43, 7698-7706.
179. Magzoub, M.; Eriksson, L.E.; Gräslund, A. Conformational states of the cell-penetrating peptide penetratin when interacting with phospholipid vesicles: effects of surface charge and peptide concentration. Biochim. Biophys. Acta 2002, 1563, 53-63.
180. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8, 848-866
181. Pooga, M.; Hällbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J. 1998, 12, 67-77.
182. Lindgren, M.; Hällbrink, M.; Prochiantz, A.; Langel, U. Cell-penetrating peptides. Trends Pharmacol. Sci. 2000, 21, 99-103.
183. Fittipaldi, A.; Ferrari, A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram, F.; Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins, J. Biol. Chem. 2003, 278, 34141-34149.
184. Simeoni, F.; Morris, M.C.; Heitz, F.; Divita, G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 2003, 31, 2717-2724.
185. Suzuki, T.; Futaki, S.; Niwa, M.; Tanaka, S.; Ueda, K.; Sugirua, Y. Possible existence of common internalization mechanisms among arginine rich peptides. J. Biol. Chem. 2002, 277, 2437-2443.
186. Drin, G.; Cottin, S.; Blanc, E.; Rees, A.R.; Temsamani, J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003, 278, 31192-31201.
187. Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, L. V.; Lebleu, B. Cell penetrating peptides: a reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278, 585-590.
188. Dietz, G.P.; Bähr, M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 2004, 27, 85-131.
189. Almeida, P.F.; Pokorny, A. Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 2009, 48, 8083-8093.
190. Rivas, L.; Luque-Ortega, J.R.; Fernandez-Reyes, M.; Andreu, D. Membrane-active peptides as anti-infectious agents. J. Appl. Biomed. 2010, 8, 159-167.
191. Lande, R; Gregorio, J.; Facchinetti, V.; Chatterjee, B.; Wang, Y. H.; Homey, B.; Cao, W.; Wang, Y-H.; Su, B.; Nestle, F.O.; Zal, T.; Mellman, I.;Schröder, J.M.; Liu, Y.J.; Gilliet, M. title type=contributor>Plasmacytoid dendritic cells sense self-DNA coupled with anti-microbial peptide. Nature 2007, 449, 564-569.
192. Zhang, X., Oglecka, K., Sandgren, S., Belting, M., Esbjörner, E.K., Nordén, B., Gräslund, A. Dual functions of the human antimicrobial peptide LL-37-Target membrane perturbation and host cell cargo delivery. Biochim. Biophys. Acta 2009, 1798, 2201-2208.
193. Hurtado, P.; Peh, C.A. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J. Immunol. 2010, 184, 1425-1435.
194. Kumagai, Y.; Takeuchi, O.; Akira, S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 2008, 60, 795-804.
195. Ito, T.; Amakawa, R.; Inaba, M.; Hori, T.; Ota, M.; Nakamura, K.; Takebayashi, M.; Miyaji, M.; Yoshimura, T.; Inaba, K.; Fukuhara, S. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J. Immunol. 2004, 172, 4253-4259.
196. Kolumam, G.A.; Thomas, S.; Thompson, L.J.; Sprent, J.; Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005, 202, 637-650.
197. Lee, S.H.; Biron, C.A. Here today--not gone tomorrow: roles for activating receptors in sustaining NK cells during viral infections. Eur. J. Immunol. 2010, 40, 923-932.
198. Fitzgerald-Bocarsly, P.; Feng, D. The role of type I interferon production by dendritic cells in host defense. Biochimie 2007, 89, 843-855.
199. Ueno, H.; Schmitt, N.; Palucka, A.K.; Banchereau, J. Dendritic cells and humoral immunity in humans. Immunol. Cell. Biol. 2010, 88, 376-380.
200. Lin, L.; Gerth, A.J.; Peng, S.L. CpG DNA redirects class-switching towards Th1-like Ig isotype production via TLR9 and MyD88. Eur. J. Immunol. 2004, 34, 1483-1487.
201. Chuang, C.M.; Monie, A.; Wu, A.; Mao, C.P.; Hung, C.F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther. 2009, 20, 303-313.
202. Büchau, A.S.; Morizane, S.; Trowbridge, J.; Schauber, J.; Kotol, P.; Bui, J.D.; Gallo, R.L. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol. 2010, 184, 369-378.
203. Kindrachuk, J.; Jenssen, H.; Elliott, M.; Townsend, R.; Nijnik, A.; Lee, S.F.; Gerdts, V.; Babiuk, L.A.; Halperin, S.A.; Hancock, R.E. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009, 27, 4662-4671.
204. Easton, D.M.; Nijnik, A.; Mayer, M.L.; Hancock, R.E. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 2009, 27, 582-590.
205. Nijnik, A.; Pistolic, J.; Wyatt, A.; Tam, S.; Hancock, R.E. Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J. Immunol. 2009, 183, 5788-5798.
206. Nagant, C.; Tré-Hardy, M.; El-Ouaaliti, M.; Savage, P.; Devleeschouwer, M.; Dehaye, J.P. Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms. Appl. Microbiol. Biotechnol. 2010, 88, 251-263.